Results 51 to 60 of about 159,104 (312)

Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice [PDF]

open access: yes, 2018
There is still an unmet need for xenotransplantation models that efficiently recapitulate normal and malignant human hematopoiesis. Indeed, there are a number of strategies to generate humanized mice and specific protocols, including techniques to ...
A Rambaldi   +17 more
core   +1 more source

Significance of Inactivated Genes in Leukemia: Pathogenesis and Prognosis

open access: yesCell Journal, 2017
Epigenetic and genetic alterations are two mechanisms participating in leukemia, which can inactivate genes involved in leukemia pathogenesis or progression.
Nazanin Heidari   +5 more
doaj   +1 more source

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

open access: yesAging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source

Long-term cultures of murine fetal liver retain very early B lymphoid phenotype. [PDF]

open access: yes, 1984
Long-term cultures of murine fetal liver have been successfully established using a modification of our in vitro bone marrow culture system (14, 15).
Denis, KA   +3 more
core  

Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. [PDF]

open access: yes, 2018
MicroRNAs, non-coding regulators of gene expression, are likely to function as important downstream effectors of many transcription factors including MYB. Optimal levels of MYB are required for transformation/maintenance of BCR-ABL-expressing cells.
Blandino, Giovanni   +15 more
core   +3 more sources

A rare presentation of chronic myeloid leukemia blast crisis

open access: yesIraqi Journal of Hematology, 2020
Chronic myeloid leukemia (CML), as the name suggests, is a chronic disorder in which granulocytes undergo dysregulated production and uncontrolled proliferation. Majority of CML patients present during the chronic phase (CP) of the disease.
P S Shruthi   +3 more
doaj   +1 more source

Chronic Hypoxia Disrupts Spermatogenesis Through ASXL2–EZH2–Mediated Microtubule Destabilization

open access: yesAdvanced Science, EarlyView.
This study reveals the mechanism by which chronic hypoxia impairs spermatogenesis via the ASXL2–EZH2 axis, hindering the transition of spermatids from round to elongated forms. Key findings reveal that under hypoxic conditions, downregulated ASXL2 expression reduces EZH2 binding to the CEP162 promoter, leading to decreased H3K27me3 modification and ...
Jun Yin   +11 more
wiley   +1 more source

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms [PDF]

open access: yes, 2011
Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities,
Agirre, Xabier   +34 more
core  

Epidemiology of leukemia and multiple myeloma in golestan, Iran [PDF]

open access: yes, 2013
Background: The aim of this paper was to present the incidence rates of leukemia and multiple myeloma (MM) in Golestan province located in northeastern Iran during 2004-2009. Materials and Methods: This was a descriptive cross-sectional study.
Jahangirrad, A.   +5 more
core   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy